Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Non-Current Assets (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Non-Current Assets readings, the most recent being $11.2 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 5.66% to $11.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $45.4 million, a 7.48% decrease, with the full-year FY2025 number at $11.2 million, down 5.66% from a year prior.
  • Non-Current Assets hit $11.2 million in Q4 2025 for Avalo Therapeutics, down from $11.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $18.4 million in Q4 2021 to a low of $11.2 million in Q4 2025.
  • Median Non-Current Assets over the past 5 years was $16.7 million (2023), compared with a mean of $14.9 million.
  • Biggest five-year swings in Non-Current Assets: rose 5.75% in 2022 and later dropped 26.3% in 2024.
  • Avalo Therapeutics' Non-Current Assets stood at $18.4 million in 2021, then dropped by 7.72% to $17.0 million in 2022, then dropped by 25.68% to $12.6 million in 2023, then decreased by 6.0% to $11.8 million in 2024, then decreased by 5.66% to $11.2 million in 2025.
  • The last three reported values for Non-Current Assets were $11.2 million (Q4 2025), $11.3 million (Q3 2025), and $11.4 million (Q2 2025) per Business Quant data.